Sangamo BioSciences Announces Presentation at the 2014 Morgan Stanley Global Healthcare Conference - KTVN Channel 2 - Reno Tahoe News Weather, Video -

Sangamo BioSciences Announces Presentation at the 2014 Morgan Stanley Global Healthcare Conference

  • Wendy Damonte's Health Watch ReportsMore>>

  • Request Remind Me 2 Kit

    Request a Remind Me 2 Kit

         More >>
  • Ask the Doctor: Pediatric Optometry

    Ask the Doctor: Pediatric Optometry

    Monday, September 15 2014 7:12 PM EDT2014-09-15 23:12:27 GMT
    Pediatric optometry is the focus of tonight's Ask the Doctor segment.More >>
    Pediatric optometry is the focus of tonight's Ask the Doctor segment.
    More >>
  • Premature Baby Heart Defect

    Premature Baby Heart Defect

    Monday, September 15 2014 2:35 PM EDT2014-09-15 18:35:05 GMT

    Specialists in Los Angeles have developed a minimally-invasive technique that corrects a common but potentially life-threatening heart problem in premature babies.

    More >>

    Specialists in Los Angeles have developed a minimally-invasive technique that corrects a common but potentially life-threatening heart problem in premature babies.

    More >>

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Sangamo BioSciences, Inc.

RICHMOND, Calif., Sept. 3, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 9:10 am ET on Wednesday, September 10, 2014, at the 2014 Morgan Stanley Global Healthcare Conference. The conference is being held in New York.

Sangamo BioSciences, Inc.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS (SB-728-T) and NGF-AAV for Alzheimer's disease (CERE-110). Sangamo's other therapeutic programs are focused on monogenic and rare diseases.  The company has formed a strategic collaboration with Shire International GmbH to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases, and with Biogen Idec for hemoglobinopathies, such as sickle cell disease and beta-thalassemia. It has also established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

Logo - http://photos.prnewswire.com/prnh/20130102/SF35903LOGO

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and Sarkes Tarzian, Inc. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.